Chemotherapy‐induced cardiotoxicity: current practice and prospects of prophylaxis

[1]  G. Dukart,et al.  Mitoxantrone: an overview of safety and toxicity , 2004, Investigational New Drugs.

[2]  P. Voûte,et al.  Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Nahata,et al.  Cardiotoxicity of Chemotherapeutic Agents , 2000 .

[4]  M. Adamcová,et al.  Anthracycline-induced cardiotoxicity. , 2000, Acta medica.

[5]  M. Nahata,et al.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. , 2000, Drug safety.

[6]  E. Winer,et al.  American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Boucek,et al.  Persistent effects of doxorubicin on cardiac gene expression. , 1999, Journal of molecular and cellular cardiology.

[8]  J. Hartikainen,et al.  Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non‐Hodgkin's lymphoma , 1999, European journal of haematology.

[9]  T. Helenius,et al.  Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. , 1998, Medical and pediatric oncology.

[10]  S. Lipshultz,et al.  Epidemiology of anthracycline cardiotoxicity in children and adults. , 1998, Seminars in oncology.

[11]  R. Nagai,et al.  Elevated B-type natriuretic peptide levels after anthracycline administration. , 1998, American heart journal.

[12]  S. Lipsitz,et al.  Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. , 1997, Circulation.

[13]  B. Pau,et al.  Cardiac troponin I in patients with hematologic malignancies , 1997, Coronary artery disease.

[14]  J. Krischer,et al.  Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Swain,et al.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Frishman,et al.  Cardiovascular toxicity with cancer chemotherapy. , 1996, Current problems in cancer.

[17]  M. Siimes,et al.  Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. , 1996, European journal of cancer.

[18]  J. Yamashita,et al.  Plasma endothelin‐1 As a marker for doxorubicin cardiotoxicity , 1995, International journal of cancer.

[19]  E J Orav,et al.  Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. , 1995, The New England journal of medicine.

[20]  F. Bu'Lock,et al.  Increased risk of cardiac dysfunction after anthracyclines in girls. , 1995, Medical and pediatric oncology.

[21]  Y. Cottin,et al.  Impairment of diastolic function during short-term anthracycline chemotherapy. , 1995, British heart journal.

[22]  M. Ogawa,et al.  Plasma endothelin-1 and doxorubicin cardiotoxicity. , 1994, The New England journal of medicine.

[23]  H. Gibbs,et al.  Cardiac diastolic function in pediatric patients receiving doxorubicin. , 1994, Acta oncologica.

[24]  H. Schulman,et al.  Cyclophosphamide cardiac injury mimicking acute myocardial infarction. , 1993, Bone marrow transplantation.

[25]  S. Gardner,et al.  High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. , 1993, Bone marrow transplantation.

[26]  K. Sridhar,et al.  Detection of Early Anthracycline Cardiotoxicity by Monitoring the Peak Filling Rate , 1993, American journal of clinical oncology.

[27]  F. Ognibene,et al.  High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction , 1993, Annals of Internal Medicine.

[28]  J. Moreb,et al.  Outcome of clinical congestive heart failure induced by anthracycline chemotherapy , 1992, Cancer.

[29]  S. Wadler,et al.  Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. , 1992, Journal of the National Cancer Institute.

[30]  P. Soulié,et al.  Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Kupersmith,et al.  Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. , 1992, Journal of the American College of Cardiology.

[32]  M. Bauch,et al.  Atrial natriuretic peptide as a marker for doxorubicin‐induced cardiotoxic effects , 1992, Cancer.

[33]  V. Ferrans,et al.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Steinherz,et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.

[35]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[36]  P. Ghezzi,et al.  Preliminary study on behaviour of atrial natriuretic factor in anthracycline-related cardiac toxicity. , 1991, International journal of clinical pharmacology research.

[37]  A. Bianco,et al.  A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer , 1989, Cancer.

[38]  H. Pouleur,et al.  Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. , 1989, American heart journal.

[39]  R. Kloner,et al.  Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  F. Crippa,et al.  Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin). , 1989, European journal of cancer & clinical oncology.

[41]  G. Hausdorf,et al.  Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. , 1988, British heart journal.

[42]  V. Ferrans,et al.  Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. , 1988, The New England journal of medicine.

[43]  J. Verweij,et al.  A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C , 1988, Medical oncology and tumor pharmacotherapy.

[44]  R. Kloner,et al.  5‐Fluorouracil Cardiotoxicity: Left Ventricular Dysfunction and Effect of Coronary Vasodilators , 1987, The American journal of the medical sciences.

[45]  D. V. Von Hoff,et al.  Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. , 1987, Cancer treatment reports.

[46]  P. Sager,et al.  Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. , 1987, The American journal of medicine.

[47]  W. Yasnoff,et al.  Alterations in left ventricular diastolic function with doxorubicin therapy. , 1987, Journal of the American College of Cardiology.

[48]  S. Steinberg,et al.  Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. , 1986, Archives of surgery.

[49]  M. Goldberg,et al.  Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. , 1986, Blood.

[50]  U. Baandrup,et al.  Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. , 1986, British heart journal.

[51]  G. Bonadonna,et al.  Phase II study of doxorubicin versus epirubicin in advanced breast cancer. , 1986, Cancer treatment reports.

[52]  R. Gelber,et al.  The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. , 1986, Medical and pediatric oncology.

[53]  N. Geller,et al.  A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Brambilla,et al.  Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C , 1985, Medical oncology and tumor pharmacotherapy.

[55]  C. Pegelow,et al.  Endomyocardial biopsy to monitor anthracycline therapy in children. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  F. Torti,et al.  Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. , 1983, Annals of internal medicine.

[57]  M. Goris,et al.  Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. , 1983, American heart journal.

[58]  R. Virmani,et al.  Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. , 1983, The American journal of cardiology.

[59]  F. Ganzina.  4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. , 1983, Cancer treatment reviews.

[60]  R. Labianca,et al.  Cardiac Toxicity of 5-Fluorouracil: A Study on 1083 Patients , 1982, Tumori.

[61]  M. Iatropoulos,et al.  Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology. , 1982, Cancer treatment reports.

[62]  B. M. Henderson,et al.  Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations. , 1982, Cancer treatment reports.

[63]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[64]  J. Mason,et al.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. , 1981, American heart journal.

[65]  A. Lewis,et al.  Recovery of left ventricular function following discontinuation of anthracycline chemotherapy in children. , 1981, Pediatrics.

[66]  J. Gottdiener,et al.  Cardiotoxicity associated with high-dose cyclophosphamide therapy. , 1981, Archives of internal medicine.

[67]  P. Steinherz,et al.  Cardiac changes with cyclophosphamide. , 1981, Medical and pediatric oncology.

[68]  T. Pajak,et al.  Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. , 1980, Cancer treatment reports.

[69]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[70]  H. von Melchner,et al.  Adriamycin cardiotoxicity: a survey of 1273 patients. , 1979, Cancer treatment reports.

[71]  G. Hortobagyi,et al.  Adriamycin and mitomycin C: possible synergistic cardiotoxicity. , 1978, Cancer treatment reports.

[72]  Randolph P. Martin,et al.  Early anthracycline cardiotoxicity. , 1978, The American journal of medicine.

[73]  M. Billingham,et al.  Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. , 1978, JAMA.

[74]  Ferrans Vj.  Overview of cardiac pathology in relation to anthracycline cardiotoxicity. , 1978, Cancer treatment reports.

[75]  J. Mason,et al.  Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. , 1978, Annals of internal medicine.

[76]  V. Ferrans.  Overview of cardiac pathology in relation to anthracycline cardiotoxicity. , 1978, Cancer treatment reports.

[77]  A. Weiss,et al.  Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity , 1977, Cancer.

[78]  A. Weiss,et al.  Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. , 1976, Cancer treatment reports.

[79]  D. Karnofsky,et al.  Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia , 1967, Cancer.